X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Texas Red Streptavidin antibody

RRID:AB_2336754

Antibody ID

AB_2336754

Target Antigen

Proper Citation

(Vector Laboratories Cat# SA-5006, RRID:AB_2336754)

Clonality

unknown

Vendor

Vector Laboratories

Cat Num

SA-5006

Publications that use this research resource

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.

  • Seaman S
  • Cancer Cell
  • 2017 Apr 10

Literature context:


Abstract:

Targeting the tumor vasculature with antibody-drug conjugates (ADCs) is a promising anti-cancer strategy that in order to be realized must overcome several obstacles, including identification of suitable targets and optimal warheads. Here, we demonstrate that the cell-surface protein CD276/B7-H3 is broadly overexpressed by multiple tumor types on both cancer cells and tumor-infiltrating blood vessels, making it a potentially ideal dual-compartment therapeutic target. In preclinical studies CD276 ADCs armed with a conventional MMAE warhead destroyed CD276-positive cancer cells, but were ineffective against tumor vasculature. In contrast, pyrrolobenzodiazepine-conjugated CD276 ADCs killed both cancer cells and tumor vasculature, eradicating large established tumors and metastases, and improving long-term overall survival. CD276-targeted dual-compartment ablation could aid in the development of highly selective broad-acting anti-cancer therapies.

Funding information:
  • Intramural NIH HHS - ZIA BC010578-13()
  • Intramural NIH HHS - ZIA BC010736-11()